Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis

ClinicalTrials.gov ID: NCT06218290

Public ClinicalTrials.gov record NCT06218290. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 8:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Multidose, Study to Assess the Tolerability and Pharmacokinetics of Oxylanthanum Carbonate at Clinically Effective Doses in Patients With Chronic Kidney Disease on Dialysis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this clinical study is to test the tolerability of oxylanthanum carbonate (OLC) in patients with chronic kidney disease on hemodialysis and have hyperphosphatemia (too much phosphorus in their blood). The main question it aims to answer is whether patients taking OLC for hyperphosphatemia are able to tolerate the drug. Participants will continue with their scheduled dialysis treatments and replace their current phosphate binder drug with OLC.

Study identification

NCT ID
NCT06218290
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Unicycive Therapeutics, Inc
Industry
Enrollment
106 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 14, 2023
Primary completion
May 28, 2024
Completion
May 28, 2024
Last update posted
Jun 23, 2024

2023 – 2024

United States locations

U.S. sites
7
U.S. states
6
U.S. cities
6
Facility City State ZIP Site status
US Renal Care Pine Bluff Arkansas 71603
US Renal Care Fort Myers Florida 33912
US Renal Care Gallup New Mexico 87301
US Renal Care Cheektowaga New York 14215
US Renal Care Toledo Ohio 43613
US Renal Care San Antonio Texas 78211
Clinical Advancement Center, PLLC San Antonio Texas 78212

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Recently updated Chronic Kidney Disease Requiring Chronic Dialysis trials

Other public records listing Chronic Kidney Disease Requiring Chronic Dialysis. Sorted by last update posted; newest first. Not a recommendation.

All Chronic Kidney Disease Requiring Chronic Dialysis trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06218290, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 23, 2024 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06218290 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →